[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.172.233.2. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 20, 1965

Busulfan (Myleran) for Myelocytic Leukemia

Author Affiliations

Brookline, Mass

Philadelphia

JAMA. 1965;193(12):1063-1064. doi:10.1001/jama.1965.03090120071031

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

To the Editor:—  In your issue of July 19 (193:255, 1965), there is a question in regard to the treatment of chronic myelocytic leukemia. This is answered by Dr. John W. Frost with the unequivocal statement that "Busulfan (Myleran) is the treatment of choice in chronic myelocytic leukemia." Although this may be true, I have seen no report of the results of treatment with Busulfan, which are comparable to the number of cases treated, or the results of treatment, reported as the result of treatment by means of x-ray or radioactive phosphorus. J. H. Lawrence reported on the latter in 1954; Osgood and associates reported on a comparison of x-ray treatment with that of irradiated phosphorus in 1955; also, a report of my treatment has appeared in a relatively small series, published both in Germany and America, in 1961.Until it has been demonstrated by adequate comparisons, it seems

First Page Preview View Large
First page PDF preview
First page PDF preview
×